IMUNON to Host R&D Day on September 18th

Stock Information for NYSE LISTED TEST STOCK FOR CTS AND CQS

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NYSE LISTED TEST STOCK FOR CTS AND CQS

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.